Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | PLAU | P00749 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.54 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.54 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Benzylcarbamate SCHEMBL1136818 | 0.90 | PLAU (0.70) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| Benzyl Benzylcarbamate SCHEMBL19810513 | 0.89 | PLAU (0.68) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| Benzyl Benzylcarbamate SCHEMBL9998166 | 0.89 | PLAU (0.68) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| Benzyl Benzylcarbamate SCHEMBL28413454 | 0.89 | PLAU (0.68) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| SCHEMBL5931079 | 0.88 | PLAU (0.69) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| SCHEMBL993696 | 0.88 | HDAC1 (0.62) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| SCHEMBL6558145 | 0.88 | HDAC1 (0.62) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| SCHEMBL191161 | 0.87 | PLAU (0.68) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| SCHEMBL4766309 | 0.87 | SMN1; SMN2 (0.62) | HDAC1HDAC2HDAC3PLAUNAMPT | |
| SCHEMBL20047179 | 0.86 | PLAU (0.66) | HDAC1HDAC2HDAC3PLAUNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | disclosed |
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| CN-105682655-B | Antimicrobial compounds | 阿克塞利亚制药公司 | 2020-03-27 | — | — | CN | disclosed |
| EP-2451776-B1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | disclosed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | disclosed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | disclosed |
| CN-103965128-B | N alkoxy amide conjugates as developer | 兰休斯医疗成像公司 | 2018-04-03 | — | — | CN | disclosed |
| US-5506267-A | IMMUNOADJUVANT FOR BONE MARROW CELL GROWTH AFTERTREATMENT OF CHEMOTHERAPY OR RADIOTHERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0641776-A2 | Thioglycerol derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0372486-B1 | Benzoic-acid phenylacetic-acid derivatives, their preparation and their use as medicines | HOFFMANN LA ROCHE (CH) | 1994-06-01 | — | — | EP | disclosed |
| US-5039805-A | Novel benzoic and phenylacetic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0048433-B1 | NOVEL AMIDINE COMPOUNDS, PROCESS FOR PRODUCING SAME AND ANTI-COMPLEMENT AGENT COMPRISING THEM | TORII & CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4570006-A | ANTITHROMBIN; ENZYME AND HORMONE INHIBITORS | TORII & CO. LTD. (JP) | 1986-02-11 | — | — | US | disclosed |
| US-4532255-A | Amidine compounds and anticomplement agent comprising same | TORII & CO., LTD. (JP) | 1985-07-30 | — | — | US | disclosed |
| US-4514416-A | Amidine compound, process for producing same and anti-complement agent comprising same | TORII & CO. LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| US-4454338-A | 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE | TORII & CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | HDAC1 423/4885HDAC2 656/4885HDAC3 556/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | HDAC1 423/4885HDAC2 656/4885HDAC3 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.